2010 Molecular Biology of Hepatitis B Viruses Meeting

2010年乙型肝炎病毒分子生物学会议

• 批准号: 7915035
• 负责人: Adam Zlotnick
• 金额: $ 1.8万
• 依托单位: HEPATITIS B FOUNDATION
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-08-01 至 2011-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7915035
• 关键词: Academia; Acute Hepatitis; Address; Anniversary; Antiviral Agents; Basic Science; Cessation of life; Chronic; Chronic Hepatitis B; Cirrhosis; Collaborations; Communities; Educational workshop; Foundations; Funding; Hepadnaviridae; Hepatitis B; Hepatitis B Vaccines; Hepatitis B Virus; Hepatitis Delta Virus; Immune response; Individual; Infection; International; Lead; Liver Failure; Location; Malignant Neoplasms; Malignant neoplasm of pancreas; Minority; Molecular Biology; Morbidity - disease rate; Oral; Population; Primary carcinoma of the liver cells; Property; Public Health; Request for Proposals; Research Personnel; Retroviridae; Scientist; Series; Simian B disease; Southeastern Asia; Taiwan; Therapeutic; Time; Underrepresented Minority; United States National Institutes of Health; Universities; Vaccines; Virus Diseases; Work; cost; meetings; posters; response; structural biology; virology

DESCRIPTION (provided by applicant): Approximately 25% of the earth's population, 2 billion people, have been infected by Hepatitis B Virus (HBV). Approximately 360 million people suffer from chronic infection. Chronic HBV contributes to the deaths of some 600,000 people annually mainly by liver failure, cirrhosis, and hepatocellular carcinoma. In addition to significant morbidity, acute HBV infection is correlated with pancreatic cancer. Approximately 15 million HBV victims are co-infected with Hepatitis Delta Virus, which can increase the chance of liver failure and cancer. New infections continue to arise, despite the availability of a vaccine, due to the ~10% non-response rate and underutilization of the vaccine due to cost and other issues. For those with chronic HBV the vaccine is not therapeutic. The available antiviral approaches are expensive, rarely clear the infection, and can lead to a serious rebound when therapy is terminated. This proposal requests funds to support the 2010 Molecular Biology of Hepatitis B Viruses Meeting to be held in Taipei, Taiwan from October 9 -13, 2010. The Hepatitis B meeting is a forum for the truly international community of researchers focusing on HBV and the closely associated HDV. For the first time this meeting will be held in Southeast Asia, where as much as 20% of the population has chronic HBV. 2010 will mark the 25th anniversary of the first HBV meeting, organized by Harold Varmus and Jesse Summers. Since then, the HBV meeting has introduced a continuous series of broad-reaching advances to the virology community. Because so much scientific progress arises from competition, collaboration, and discussion, it can be argued that the HBV meeting has contributed to these advances. It is, therefore, imperative that basic research and the scientific exchange among those studying HBV/HDV continue and the annual HBV meeting represents the venue at which this can occur. The 2010 meeting will continue in this tradition by emphasizing discussion and networking in two poster sessions, 10 oral sessions, a workshop on the structural biology of hepadnaviruses, and keynote addresses on innate immune response and spumaviridae (a retrovirus genus with some distinctly HBV-like properties). Because of its location, a great effort has been made to minimize the cost of the meeting by working with the Academia Sinica campus. Furthermore, the Hepatitis B Foundation which has administratively supported this meeting since 2005, making its staff available for organizing the meeting and publicizing it, especially to universities with large numbers of underrepresented minorities. In order to allow the participation of junior and minority investigators, support from the NIH to help defray the meeting costs of junior scientists is requested. Limited support for meeting materials and organizational functions is also needed. The 2010 Molecular Biology of Hepatitis B Viruses Meeting, the 26th in the series, is the definitive meeting that brings together basic scientists in the field of Hepatitis B Virus (HBV) and Hepatitis Delta Virus (HDV) from around the world. HBV is a major global and US public health problem with approximately 2 billion individuals infected by HBV, 360 million chronically, resulting in an annual rate of approximately 600,000 deaths due to HBV and HBV/HDV-induced liver failure, cirrhosis, and hepatocellular carcinoma. The meeting is a critical and internationally well-recognized platform for exchange of information in basic research on HBV and HDV infections.

描述（由申请人提供）：大约25％的地球人口（20亿人）被乙型肝炎病毒感染（HBV）。大约3.6亿人患有慢性感染。慢性HBV每年大约有60万人死亡，主要是肝衰竭，肝硬化和肝细胞癌死亡。除了明显的发病率外，急性HBV感染与胰腺癌相关。大约有1500万HBV受害者与乙型肝炎病毒共感染，这可以增加肝衰竭和癌症的机会。尽管有疫苗，但由于成本和其他问题而导致的疫苗未充分利用，尽管有疫苗的利用率约为10％，但仍会出现新的感染。对于患有慢性HBV的人，疫苗没有治疗性。可用的抗病毒方法很昂贵，很少清除感染，并且在终止治疗时会导致严重的反弹。该提案要求资金支持2010年10月9日至13日在台湾台北举行的2010年丙型肝炎病毒会议的分子生物学。丙型肝炎B会议是一个真正的国际研究人员社区的论坛，专注于HBV和密切相关的HDV。这次会议首次将在东南亚举行，多达20％的人口患有慢性HBV。 2010年将纪念由Harold Varmus和Jesse Summers组织的首次HBV会议25周年。从那以后，HBV会议为病毒学社区推出了一系列不断的广泛进步。因为竞争，协作和讨论造成了如此之多的科学进步，因此可以说，HBV会议为这些进步做出了贡献。因此，必须在研究HBV/HDV的人们之间进行基础研究和科学交流，而年度HBV会议则代表了发生这种情况的场所。 2010年的会议将在这一传统中继续进行，通过强调两次海报会议，10次口腔会议，肝癌结构生物学的讲习班以及有关先天免疫反应的主题演讲和Spumaviridae（一个逆转录病毒属，具有独特的HBV属性）。由于其位置，已经付出了巨大的努力来最大程度地降低会议成本，并与Sinica校园合作。此外，自2005年以来一直在行政上支持本次会议的乙型肝炎基金会，使其员工可以组织会议和宣传会议，尤其是对大量代表性不足的少数群体的大学。为了允许初级和少数族裔调查员的参与，NIH的支持以帮助支付初级科学家的会议费用。对会议材料和组织功能的支持有限。该系列的第26届丙型肝炎病毒会议的2010年分子生物学是将世界各地的乙型肝炎病毒（HBV）和乙型肝炎领域的基础科学家汇集在一起​​的确定会议。 HBV是一个主要的全球和美国公共卫生问题，大约有20亿人感染了HBV，3.6亿长期，由于HBV和HBV/HDV诱导的肝脏衰竭，cirrhosis和Hepatocolular Carcinoma造成的年率约为60万人。这次会议是一个关键且国际公认的平台，用于在HBV和HDV感染基础研究中提供信息。